KR20190073450A - 분산성 조성물 - Google Patents

분산성 조성물 Download PDF

Info

Publication number
KR20190073450A
KR20190073450A KR1020197014202A KR20197014202A KR20190073450A KR 20190073450 A KR20190073450 A KR 20190073450A KR 1020197014202 A KR1020197014202 A KR 1020197014202A KR 20197014202 A KR20197014202 A KR 20197014202A KR 20190073450 A KR20190073450 A KR 20190073450A
Authority
KR
South Korea
Prior art keywords
composition
peg
amino
pharmaceutically acceptable
diluent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197014202A
Other languages
English (en)
Korean (ko)
Inventor
하르샤드 파탄카르
니콜라스 마르타 펠릭스 고이바에르츠
라잔 고팔 라잔 랑가
Original Assignee
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 filed Critical 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니
Priority to KR1020247001197A priority Critical patent/KR102861006B1/ko
Publication of KR20190073450A publication Critical patent/KR20190073450A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197014202A 2016-10-24 2017-10-23 분산성 조성물 Ceased KR20190073450A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247001197A KR102861006B1 (ko) 2016-10-24 2017-10-23 분산성 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201621036404 2016-10-24
IN201621036404 2016-10-24
PCT/EP2017/077030 WO2018077815A1 (en) 2016-10-24 2017-10-23 Dispersible compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247001197A Division KR102861006B1 (ko) 2016-10-24 2017-10-23 분산성 조성물

Publications (1)

Publication Number Publication Date
KR20190073450A true KR20190073450A (ko) 2019-06-26

Family

ID=60262899

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197014202A Ceased KR20190073450A (ko) 2016-10-24 2017-10-23 분산성 조성물
KR1020247001197A Active KR102861006B1 (ko) 2016-10-24 2017-10-23 분산성 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247001197A Active KR102861006B1 (ko) 2016-10-24 2017-10-23 분산성 조성물

Country Status (21)

Country Link
US (2) US11065198B2 (https=)
EP (2) EP4248947A3 (https=)
JP (2) JP7197474B2 (https=)
KR (2) KR20190073450A (https=)
CN (1) CN110191704A (https=)
CA (1) CA3039562A1 (https=)
DK (1) DK3528791T3 (https=)
ES (1) ES2970870T3 (https=)
FI (1) FI3528791T3 (https=)
HR (1) HRP20240118T1 (https=)
HU (1) HUE064823T2 (https=)
LT (1) LT3528791T (https=)
MA (1) MA46563B1 (https=)
MX (1) MX2019004767A (https=)
PL (1) PL3528791T3 (https=)
PT (1) PT3528791T (https=)
RS (1) RS65159B1 (https=)
SI (1) SI3528791T1 (https=)
SM (1) SMT202400060T1 (https=)
TW (1) TWI821163B (https=)
WO (1) WO2018077815A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
CN115397422A (zh) 2019-11-29 2022-11-25 西皮欧生命科学有限公司 包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
GB202211231D0 (en) * 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181966A1 (en) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Compression-coated dispersible tablets
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
KR101140785B1 (ko) 2002-08-09 2012-05-03 얀센 파마슈티카 엔.브이. 4-〔〔4-〔〔4-（2-시아노에테닐）-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법
ATE508748T1 (de) 2004-09-02 2011-05-15 Janssen Pharmaceutica Nv Salz von 4-ää4-ää4-(2-cyanoethenyl)-2,6- dimethylphenylüaminoü-2- pyrimidinylüaminoübenzonitril.
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
UA92469C2 (en) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
EP2040671B1 (en) 2006-06-23 2018-01-24 Janssen Sciences Ireland UC Aqueous suspensions of tmc278
US20160346198A1 (en) 2014-02-05 2016-12-01 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
WO2015136294A1 (en) * 2014-03-13 2015-09-17 Cipla Limited Pharmaceutical composittion comprising rilpivirine
CA2949094A1 (en) * 2014-05-16 2015-11-19 Vivus, Inc. Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use

Also Published As

Publication number Publication date
HRP20240118T1 (hr) 2024-04-12
JP2020500168A (ja) 2020-01-09
SMT202400060T1 (it) 2024-03-13
RU2019115672A (ru) 2020-11-24
WO2018077815A1 (en) 2018-05-03
LT3528791T (lt) 2024-05-27
KR20240011873A (ko) 2024-01-26
PT3528791T (pt) 2024-02-19
EP4248947A2 (en) 2023-09-27
JP7197474B2 (ja) 2022-12-27
MX2019004767A (es) 2019-07-01
CN110191704A (zh) 2019-08-30
ES2970870T3 (es) 2024-05-31
SI3528791T1 (sl) 2024-04-30
JP2023011659A (ja) 2023-01-24
RS65159B1 (sr) 2024-02-29
EP3528791B1 (en) 2023-12-06
KR102861006B1 (ko) 2025-09-16
MA46563A (fr) 2019-08-28
EP4248947A3 (en) 2023-11-22
US20220008333A1 (en) 2022-01-13
HUE064823T2 (hu) 2024-04-28
TW201828927A (zh) 2018-08-16
EP3528791A1 (en) 2019-08-28
MA46563B1 (fr) 2024-01-31
RU2019115672A3 (https=) 2021-01-21
BR112019007564A2 (pt) 2019-07-02
PL3528791T3 (pl) 2024-04-02
US20200069579A1 (en) 2020-03-05
US11065198B2 (en) 2021-07-20
DK3528791T3 (da) 2024-01-29
TWI821163B (zh) 2023-11-11
FI3528791T3 (fi) 2024-01-30
CA3039562A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
KR102631986B1 (ko) 분산성 조성물
JP2023011659A (ja) 分散性組成物
HK1210029A1 (en) Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile
HK40101645A (en) Dispersible compositions
CN101068597B (zh) 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐
KR101276571B1 (ko) 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 푸마레이트
HK40013979B (en) Dispersible compositions
HK40013979A (en) Dispersible compositions
RU2826218C2 (ru) Диспергируемые композиции
BR112019007564B1 (pt) Composições dispersíveis, seu processo de fabricação e uso de rilpivirina
HK40013937A (en) Dispersible compositions
CA2973301C (en) Dispersible compositions comprising bedaquiline fumarate
MX2007002594A (es) Fumarato de 4-((4-((4- (2-cianoetenil)-2, 6-dimetilfenil) amino)-2-pirimidinil) amino) benzonitrilo.
HK1112862B (en) Furamate of 4-((4-(4-(2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
EA042247B1 (ru) Диспергируемые композиции
OA18325A (en) Dispersible compositions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104